44483637 2025-01-01 2025-12-31 44483637 2025-01-01 2025-12-31 auditor_1 44483637 2025-01-01 2025-12-31 memberOfBoardIdentifier_1 44483637 2025-01-01 2025-12-31 memberOfBoardIdentifier_1 44483637 2025-01-01 2025-12-31 memberOfBoardIdentifier_2 44483637 2025-01-01 2025-12-31 memberOfBoardIdentifier_3 44483637 2024-01-01 2024-12-31 44483637 2025-12-31 44483637 2024-12-31 44483637 2024-12-31 fsa:ContributedCapitalMember 44483637 2024-12-31 fsa:RetainedEarningsMember 44483637 2025-01-01 2025-12-31 fsa:ContributedCapitalMember 44483637 2025-01-01 2025-12-31 fsa:RetainedEarningsMember 44483637 2025-12-31 fsa:ContributedCapitalMember 44483637 2025-12-31 fsa:RetainedEarningsMember 44483637 2024-12-31 fsa:CompletedDevelopmentProjectsMember 44483637 2025-12-31 fsa:CompletedDevelopmentProjectsMember 44483637 2025-01-01 2025-12-31 fsa:CompletedDevelopmentProjectsMember 44483637 2025-12-31 fsa:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstrumentsMember 44483637 2024-12-31 fsa:ConvertibleProfitYieldingOrDividendYieldingLongtermDebtInstrumentsMember iso4217:DKK pure 2024-01-01 2024-12-31 2026-06-24 44483637 2026-06-24 Reporting class B KPMG 2100 København Ø Dampfærgevej 28 25578198 Auditor's reports (Other non-assurance reports) KPMG 25578198 true Annual report Matias Søndergaard The Board of Directors and the Executive Board have today discussed and approved the annual report for Coco Care ApS for the financial year 1 January - 31 December 2025. The annual report, which has not been audited, is presented in accordance with the Danish Financial Statements Act. In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2025 and of the results of the Company's operations for the financial year 1 January - 31 December 2025. Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review. We recommend that the annual report be approved at the annual general meeting. Management confirms that the Company fulfils the requirement to be exempt from audit. Copenhagen 2026-06-24 Matias Søndergaard Director Mikkel Lucas Overby Chairman Karen Skjerbæk Jørgensen Matias Søndergaard Auditor's report on compilation of financial statements To the Management of Coco Care ApS We have compiled the financial statements of Coco Care ApS for the financial year 1 January - 31 December 2025 based on the Company's bookkeeping records and other information provided by you.The financial statements comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies.We performed our work in accordance with ISRS 4410 Compilation Engagements.We have applied our professional expertise in accounting and financial reporting to assist you in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant provisions of the Danish Auditor Act, including the requirements for independence, and International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code), which is based on fundamental principles of integrity, objectivity, professional competence and due care.These financial statements and the accuracy and completeness of the information used to compile them are your responsibility. Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion as to whether these financial statements are prepared in accordance with the Danish Financial Statements Act. Copenhagen 2026-06-24 KPMG 25578198 Simon Vinberg Andersen State Authorised Public Accountant mne35458 Coco Care ApS Nyhavn 41, st. DK-1051 København K 44483637 2023-12-08 København 2025-01-01 2025-12-31 Principal activities The company's purpose is development and delivery of products and services within Health-tech and related business areas as deemed appropriate by the board. Development in activities and financial position The Company's income statement for 2025 shows a loss of DKK 1,928,923 as against a profit of DKK 8,598,699 in 2024. Equity in the Company's balance sheet at 31 December 2025 stood at DKK 2,197,419 as against DKK 4,126,342 at 31 December 2024. The financial year was in line with forecast, and results for the year are considered satisfactory. Events after the balance sheet date No events have occurred after the balance sheet date of material importance to the annual report for 2025. -685937 8950942 826455 517203 412368 412368 -1924760 8021371 274 2495 4437 2151 -1928923 8021715 0 -576984 -1928923 8598699 0 11569000 -1928923 -2970301 3264594 3676962 58951 36451 3323545 3713413 60750 0 0 25531 8250 0 69000 25531 299890 1064133 368890 1089664 3692435 4803077 204045 204045 1993374 3922297 2197419 4126342 858968 0 61952 96006 45676 24729 528420 556000 636048 676735 1495016 676735 3692435 4803077 204045 3922297 0 -1928923 204045 1993374 The annual report of Coco Care ApS for 2025 has been prepared in accordance with the provisions applying to reporting class B entities under the Danish Financial Statements Act with opt-in from higher reporting classes.The accounting policies used in the preparation of the financial statements are consistent with those of last year. Gross profit/loss Pursuant to section § 32 of the danish Financial Statements Act, the company has decided only to disclose gross profit Gross profit comprises revenue, cost of sales and other external costs. Revenue Income from the sale of goods, comprising the sale of products and services, are recognised in revenue when delivery and transfer of risk to the buyer have taken place, and the income may be measured reliably and is expected to be received. The date of transfer of the most significant benefits and risks is determined using standard Incoterms ®2020. Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts granted are deducted from revenue. Revenue from the sale of services is recognised on a straight-line basis in the income statement as the services are provided. Cost of sales Cost of sales comprises costs incurred to generate revenue for the year. This item also comprises direct costs for goods for resale and changes to inventory of goods for resale. Other operating income Other operating income comprises items secondary to the activities of the Company, including fair value adjustment of other equity investments. Other external costs Other external costs comprise costs for administrative expenses, costs of premises, etc. Staff costs Staff costs comprise wages and salaries, including holiday allowance, pension and other social security costs. Financial income and expenses Financial income and expenses comprise interest income and expense. Tax on profit/loss for the year Tax for the year comprises current tax for the year and changes in deferred tax, including changes in tax rates. The tax expense relating to the profit/loss for the year is recognised in the income statement at the amount attributable to the profit/loss for the year and directly in equity at the amount attributable to entries directly in equity. Intangible assets Patents, licences and trademarks are measured at cost less accumulated amortisation and impairment losses. Patents are amortised on a straight-line basis over the remaining life of the patent, licences are amortised over the contract period, however, not exceeding # years, and trademarks are amortised over their expected useful life, but no more than 10 years. Development costs and costs for internally generated rights are recognised in the income statement in the acquisition year. Gains and losses on the disposal of intangible assets are determined as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses are recognised in the income statement as other operating income or other operating costs, respectively. Financial assets Other receivables and deposits are recognised at amortised cost. Impairment of fixed assets The carrying amount of intangible assets and property, plant and equipment as well as equity investments in subsidiaries and participating interests (including associates) is subject to an annual test for indications of impairment other than the decrease in value reflected by depreciation or amortisation. Impairment tests are conducted of individual assets or groups of assets when there is an indication that they may be impaired. Write-down is made to the recoverable amount if this is lower than the carrying amount. The recoverable amount is the higher of an asset's net selling price and its value in use. The value in use is determined as the present value of the forecast net cash flows from the use of the asset or the group of assets, including forecast net cash flows from the disposal of the asset or the group of assets after the end of the useful life. Previously recognised write-downs are reversed when the basis for the write-down no longer exists. ReceivablesReceivables are measured at amortised cost.Write-down is made for bad debt losses where there is an objective indication that a receivable has been impaired. If there is an objective indication that an individual receivable has been impaired, write-down is made on an individual basis.Write-downs are calculated as the difference between the carrying amount of receivables and the present value of forecast cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate. Prepayments Prepayments comprise prepayment of costs incurred relating to subsequent financial years. Cash at bank and in hand Cash at bank and in hand comprise cash and bank deposits. EquityDividends The expected dividend payment for the year is disclosed as a separate item under equity. LiabilitiesLiabilities are measured at amortised cost. Deferred income Deferred income comprises payments received regarding income in subsequent years. 815649 513113 10806 4090 2 1 0 -576984 4123694 4123694 -446732 -412368 -859100 3264594 858968 0 Contingent liabilities, including guarantee commitments The Group's Danish entities are jointly and severally liable for tax on the Group's jointly taxed income and for certain withholding taxes such as dividend tax and royalty tax as well as for the joint registration for VAT. The jointly taxed entities' total net liability to SKAT amounted to DKK 0 at 31 December 2025. Any subsequent corrections of the taxable income subject to joint taxation or with-holding taxes on dividends, etc., may entail an increase in the entities' liability. The Group as a whole is not liable to any other parties. Other commitments, including lease obligations The Company has entered into operating lease and rental agreements amounting to DKK 225 thousand. The remaining lease term is 15 months, with an average monthly lease payment of DKK 15 thousand.